IOVA - Iovance Biotherapeutics

Set up in a shallowing base after a 150% run; wants to buy if it breaks out above 4.75 but thinks it's still early.

Strong Q1 revenue growth (38% YoY), low market cap ($1.9B), analyst target $9.50, and technical consolidation pattern with tightening pullbacks indicating accumulation.

First approved TIL cell therapy for solid tumors, strong revenue growth, analyst consensus target of $9.5 (130% upside), improving margins, strong pipeline, consolidation pattern with tightening pullbacks indicating institutional accumulation.

Biotech sector is surging while the broader market sells off. IOVA is breaking out of a two-week consolidation base with an 8.77% average daily range (high to low). The stock shows absorption patterns with decreasing retracement percentages (43% down to 11%), indicating supply being sucked out. The stock is ripping higher during the broad market selloff.

Breaking out of a two-week consolidation base during a broad market selloff. Shows classic shallowing compression pattern with supply being sucked out. $2 billion midcap with high average daily range of 8.77% offers good volatility for swing trades.